TECHi.comAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
NASDAQ · Healthcare · Profile
Amgen Inc. (AMGN) stock profile and business model
What Amgen Inc. does, how the business earns money, and how valuation, peers, ownership, and risk shape the TECHi profile.
Section freshness
Prices as of Sep 4, 4:00 PM EDT · Fundamentals checked Sep 8, 8:15 AM EDT · Statements Jun 30, 2026
Investor profile snapshot
AMGN live price, business model and key metrics
Start with the live market print, then use this profile to connect Amgen Inc.'s operating model with revenue, margins, peer context, and investor risk.
$437.23
▼ -$6.89(-1.55%)4:00 PM ET - vs previous closeiQuote as of Sep 4, 2026, 4:00 PM EDT
NASDAQ market is closed. Showing the latest available regular-session trade from Sep 4, 2026, 4:00 PM EDT.
Market data source
Long-term ranges5Y, 10Y, Since first printHide
Live price
$437.23
Live during market hours
Market cap
$236.38B
Equity scale
Analyst view
Buy
Target $389.69 (-10.87% implied)
Company · Profile
About Amgen Inc. (AMGN)
Sector, leadership, and how Amgen Inc. earns its revenue.
Healthcare
Company · Profile
About Amgen Inc. (AMGN)
Sector, leadership, and how Amgen Inc. earns its revenue.
Amgen Inc.
NASDAQ · AMGN · US
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Thousand Oaks, CA, United States
- Country
- US
- Founded
- 1983
- Employees
- 31,500
- CEO
- Mr. Robert A. Bradway
- Exchange
- NASDAQ
Business identity
Amgen Inc. company facts and operating footprint
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Thousand Oaks, CA, United States
- Founded
- 1983
- Employees
- 31,500
- CEO
- Mr. Robert A. Bradway
- Country
- US
- Exchange
- NASDAQ
Registration and filing identifiersShowHide
- Asset type
- Common Stock
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
- CIK
- 0000318154
Key metrics
AMGN valuation, revenue and margin profile
- Market cap
- $236.38B
- Equity scale
- Revenue TTM
- $38.09B
- Trailing twelve months
- Net margin
- 22.95%
- Profit after expenses
- Revenue growth
- 9.53%
- Latest YoY quarter
- Free cash flow
- $3.49B
- Reported in USD
Margin quality snapshot
Competitors
AMGN competitors and peer context
| Ticker | Company | Price | Move |
|---|---|---|---|
| ABBV | ABBV | $256.46 | -1.44% |
Risk heatmap
AMGN business risks investors should monitor
Valuation sensitivity
Elevated27.17x
Use the forward P/E and PEG context before treating the profile as cheap or expensive.
Balance-sheet flexibility
ElevatedD/E 4.44 · CR 1.37
Debt load and near-term liquidity shape how much strategic patience the company has.
Growth durability
Monitor9.53%
Latest YoY revenue growth is the first check on whether the business model is still expanding.
Market sensitivity
MonitorBeta 0.43
Higher beta can amplify drawdowns when rates, earnings expectations, or sector appetite shift.
Regulatory and operating pressure
ElevatedHealthcare
Platform rules, AI governance, export controls, and supply-chain constraints can move product timing, margins, or addressable markets.
AMGN ownership and registration profile
- Float shares
- 539.16M
- Insider ownership
- 0.23%
- Institutional ownership
- 85.14%
- Address
- One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, United States
Size & scale
- Market cap
- $236.38B
- Enterprise value
- $274.25B
- Shares outstanding
- 540.63M
- Currency
- USD
Frequently asked
Common questions.
What does Amgen Inc. do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Where does TECHi source the AMGN profile?
AMGN profile facts come from company filings and TECHi's market-data providers; any detail that is not available is left blank rather than inferred.